SCHEMBL764543

SCHEMBL764543

NC(=O)c1cc2cc(Cl)ccc2[nH]1

nearest known ligand 0.72

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
F7 P08709 1/20 0.72
F3 P13726 1/20 0.72
MEN1 O00255 2/20 0.62
KMT2A Q03164 2/20 0.62
NPC1 O15118 1/20 0.62
RAB9A P51151 1/20 0.62
SIRT1 Q96EB6 1/20 0.59
HRH4 Q9H3N8 5/20 0.57
HRH3 Q9Y5N1 3/20 0.57
FLT3 P36888 1/20 0.57
HRH1 P35367 1/20 0.55
RXFP1 Q9HBX9 1/20 0.55
SMYD3 Q9H7B4 1/20 0.55
NHERF1 O14745 2/20 0.54
PYGL P06737 1/20 0.54
GUSB P08236 1/20 0.53
DAO P14920 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29062810 0.86 ALOX15 (0.64) F7F3MEN1KMT2ANPC1
SCHEMBL2694131 0.84 F7 (0.74) F7F3MEN1KMT2ANPC1
5-Chloroindole-2-Carboxylic Acid SCHEMBL720582 0.84 F7 (1.00) F7F3MEN1KMT2ANPC1
SCHEMBL7881997 0.82 F7 (0.62) F7F3MEN1KMT2ANPC1
SCHEMBL6343336 0.82 F7 (0.72) F7F3MEN1KMT2ANPC1
SCHEMBL2729831 0.82 F7 (0.72) F7F3MEN1KMT2ANPC1
5-Chloroindole-2-Carboxylic Acid SCHEMBL6921825 0.82 F7 (0.96) F7F3MEN1KMT2ANPC1
SCHEMBL4933623 0.81 F7 (0.66) F7F3MEN1KMT2AHRH4
SCHEMBL10313791 0.81 F7 (0.66) F7F3MEN1KMT2ANPC1
Hydrochloric Acid SCHEMBL7879665 0.81 F7 (0.60) F7F3MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115028619-A SMYD inhibitors EPIZYME股份有限公司 2022-09-09 CN claimed
CN-111171040-A Dihydrofuropyran/pyridoindole derivatives and synthesis method thereof 常州大学 2020-05-19 CN claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
CN-116685576-A Cysteine protease inhibitors and methods of use thereof 美商帕迪斯生物科学公司 2023-09-01 CN disclosed
US-20230159453-A1 INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION COCRYSTAL PHARMA, INC. 2023-05-25 US disclosed
EP-4132944-A1 INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION Cocrystal Pharma, Inc. (US) 2023-02-15 EP disclosed
EP-3125883-B1 INDOLE DERIVATIVES FOR USE IN MEDICINE IOMET PHARMA LTD (GB) 2020-08-12 EP disclosed
CN-111171040-A Dihydrofuropyran/pyridoindole derivatives and synthesis method thereof 常州大学 2020-05-19 CN disclosed
CN-105037422-A Preparation method of indole phosphonate derivative UNIV SOOCHOW 2015-11-11 CN disclosed
US-8481081-B2 Pharmaceutical solid dispersions BEND RESEARCH, INC. (US) 2013-07-09 US disclosed
EP-1405852-B9 DIAMINE DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2013-03-27 EP disclosed
CN-101039666-A 3-arylthioindole-2-carboxamide derivatives and analogs thereof as inhibitors of casein kinase i AVENTIS PHARMA INC (US) 2007-09-19 CN disclosed
CN-1894238-A Diamine derivatives DAIICHI SEIYAKU CO (JP) 2007-01-10 CN disclosed
CN-1826333-A Diamine derivatives DAIICHI SEIYAKU CO (JP) 2006-08-30 CN disclosed
CN-1751025-A Diamine derivatives DAIICHI SEIYAKU CO (JP) 2006-03-22 CN disclosed
CN-1639120-A Indolamid derivatives which possess glycogenphosphorylase inhibitory activity ASTRAZENECA AB (SE) 2005-07-13 CN disclosed
CN-1283615-A New Process and intermediate PFIZER PROD INC (US) 2001-02-14 CN disclosed
US-5258362-A Enzyme inhibitors, amides with oxetane ring ABBOTT LABORATORIES (US) 1993-11-02 US disclosed
WO-1992022313-A1 RENIN INHIBITING COMPOUNDS ABBOTT LABORATORIES (US) 1992-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159453-A1 INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION VIM, ACE, ACE2 F7 717/4885F3 650/4885MEN1 1593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.